home / stock / nvcr / nvcr news


NVCR News and Press, NovoCure Limited From 10/25/18

Stock Information

Company Name: NovoCure Limited
Stock Symbol: NVCR
Market: NASDAQ
Website: novocure.com

Menu

NVCR NVCR Quote NVCR Short NVCR News NVCR Articles NVCR Message Board
Get NVCR Alerts

News, Short Squeeze, Breakout and More Instantly...

NVCR - NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2018 Results - Earnings Call Transcript

NovoCure Limited (NVCR) Q3 2018 Earnings Conference Call October 25, 2018 08:00 AM ET Executives Ashley Cordova - Senior Vice President, Finance and Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chief Financial Of...

NVCR - Midday movers: TWTR, XLNX gain; ALGN, GG lose (10/25/2018)

Gainers:  TIS +20% . TBIO +17% . SNBR +17% . LJPC +17% . ATNI +16% . IMMY +15% . TWTR +15% . XLNX +15% . TRVG +14% . MORN +14% . More news on: Orchids Paper Products Company, Translate Bio, Sleep Number Corporation, Stocks on the move, , Top stock marke...

NVCR - NovoCure 2018 Q3 - Results - Earnings Call Slides

The following slide deck was published by NovoCure in conjunction with their 2018 Q3 earnings Read more ...

NVCR - NovoCure Q3 top line up 29%

NovoCure ( NVCR ) Q3 results: Revenues: $64.8M (+29.3%); Net Loss: ($11.7M) (+1.7%); Loss Per Share: ($0.13) (unch). More news on: NovoCure, Healthcare stocks news, Earnings news and commentary, Read more ...

NVCR - NovoCure beats by $0.02, misses on revenue

NovoCure (NASDAQ: NVCR ): Q3 GAAP EPS of -$0.13 beats by $0.02 . More news on: NovoCure, Earnings news and commentary, Healthcare stocks news, Read more ...

NVCR - Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma Novocure (NASD...

NVCR - NovoCure: Projecting Glioblastoma And Mesothelioma Revenues

Shares of NovoCure ( NVCR ) were trading at $18/share when I introduced them as "revolutionizing cancer treatment" and at $21/share when I called them a "high conviction" pick. Just a few months later, shares in NovoCure trade comfortably over $45/share and for good reason. NovoCure is see...

NVCR - Novocure and Zai Lab collaborates for Tumor Treating Fields in Greater China

Novocure (NASDAQ: NVCR ) and Zai Lab (NASDAQ: ZLAB )  signs an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. More news on: NovoCure, Zai Lab Ltd., Healthcare stocks news, ...

NVCR - Autos And Housing Are Tepid - Cramer's Mad Money (9/11/18)

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday , September 11. Cramer started the show by remembering the tragic events of Sept. 11, 2001 and the collapse of Lehman Brothers. Despite that, he repeated his mantra, "There is always a bull market ...

NVCR - Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China

Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, ...

Previous 10 Next 10